By Fineline Cube 
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that it has received clinical trial clearance from the National Medical Products Administration (NMPA) for its investigational drug candidate GR1803. This bispecific antibody (BsAb) targets BCMA and CD3 and is intended for the treatment of relapsed/refractory multiple myeloma in adult patients, to be used in combination with an anti-CD38 monoclonal antibody (mAb).
Innovative Bispecific Antibody Design
GR1803 is a Category 1 biologic product constructed using a common light chain platform, resulting in a structure highly similar to conventional monoclonal antibody (mAb) molecules. This design facilitates the development of its manufacturing process and reduces the potential immunogenicity that can arise from structural deviations.
Mechanism and Advantages
The drug exhibits approximately 100-fold higher binding affinity for BCMA compared to CD3. This asymmetric affinity design allows for the effective recruitment and activation of T cells to kill tumor cells while significantly minimizing nonspecific T-cell activation mediated by CD3 binding. As a result, GR1803 is expected to reduce the potential toxic side effects associated with its injection in vivo.-Fineline Info & Tech